Table 1

Baseline characteristics

BIO-TOP study n=125DRESS study n=102
Demographics
 Age (years)*57 (12)59 (10)
 Female gender81 (65)62 (61)
 Disease duration (years)†4 (1–10)11 (6–17)
 RF positive74/123 (60)80 (78)
 ACPA positive65/116 (56)73 (72)
Disease characteristics
 DAS28-CRP*4.0 (1.1)2.2 (0.6)
 TJC†4 (2–9)0 (0–1)
 SJC†4 (1–7)0 (0–0)
 PGA, VAS 0–100 mm*‡62 (20)23 (17)
 CRP (mg/L)†5 (1–19)3 (3)
 ESR (mm/hour)†‡17 (7-31)12 (7–20)
 Calprotectin (ng/mL)†680 (433–1252)612 (475-927)
Treatment characteristics
 Number of previous bDMARDs†0 (0–1)0 (0–1)
 Current TNFi
  ADA50 (40)38 (37)
  ETN75 (60)64 (63)
 Duration current TNFi (years)†NA3 (2–6)
 Concomitant treatment
  csDMARDs97 (78)59 (58)
  MTX66 (53)46 (45)
  NSAIDs80 (64)57 (56)
  Oral glucocorticoids22 (18)5 (5)
  • Data presented as number (%) unless otherwise noted.

  • *Mean (SD).

  • †Median (p25–p75).

  • ‡Missing data BIO-TOP study; in eight patients (6%) PGA is missing and in nine patients (7%) ESR is missing. If PGA was missing, DAS28-CRP was calculated with three variables: TJC, SJC and CRP.

  • ACPA, anti-citrullinated protein antibodies; ADA, adalimumab; bDMARD, biological disease-modifying antirheumatic drug; BIO-TOP, Biologic Individual Optimised Treatment Outcome Prediction; CRP, C-reactive protein; csDMARD, conventional synthetic DMARD; DAS28-CRP, 28-joint count Disease Activity Score using CRP; DRESS, Dose Reduction Strategies of Subcutaneous TNF Inhibitors; ESR, erythrocyte sedimentation rate; ETN, etanercept; MTX, methotrexate; NA, not applicable; NSAID, non-steroidal anti-inflammatory drug; PGA, patient global assessment of disease activity; RF, rheumatoid factor; SJC, swollen joint count; TJC, tender joint count; TNFi, tumour necrosis factor inhibitor; VAS, visual analogue scale.